230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it?

230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it?

Siddharth Mane
/ Categories: Trending, Mindshare

The company has delivered returns of 14.5 per cent over the past 3 years and returns of 230 per cent over the past 5 years.

Granules India Limited, founded in 1991, is a fast-growing Indian pharmaceutical company headquartered in Hyderabad. They have vertically integrated operations, covering the manufacturing of APIs, PFIs, and FDs. With a global presence in over 80 countries and regulatory approvals from renowned organizations, they are committed to operational excellence, quality, and customer service.

Granules India Limited has received approval from the US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) filed by its subsidiary, Granules Pharmaceuticals Inc (GPI). The approval is for Acetaminophen and Ibuprofen Tablets, which are bioequivalent to the reference listed drug (RLD), Advil Dual Action with Acetaminophen Tablets.

DSIJ offers a service 'Mid Bridge' with recommendations for Mid-Cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the service details pdf here

The product will be launched through Granules Consumer Health (GCH) division. With this approval, Granules now has a total of 59 ANDA approvals from the US FDA. The Advil Dual Action brand and store brands had combined US sales of approximately USD 70 million in the past year.

The company has delivered returns of 14.5 per cent over the past 3 years and returns of 230 per cent over the past 5 years. Additionally, the company has a ROCE of 19.4 per cent and a ROE of 19.1 per cent.

On Friday, shares of the company surged by more than 0.5 per cent and made an intraday high of Rs 305.75.

Investors should keep a close eye on this stock.

Previous Article Multibagger stock under Rs 100 hits 20 per cent upper circuit as the company reports a 120 per cent jump in net profit!
Next Article Watch out for these Penny Stocks locked in the upper circuit on July 14
Rate this article:
4.1

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR